STOCK TITAN

Aimei Health signs non-binding letter to acquire Hera

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aimei Health Technology Co., Ltd. (AFJK) entered into a non-binding letter of intent with Hera Health Solutions Inc. for a proposed business combination. Under the LOI, Aimei would acquire 100% of Hera’s outstanding equity and equity equivalents in exchange for shares of the combined public company.

The LOI is non-binding on the proposed transaction, except for provisions including confidentiality and exclusivity. The transaction remains subject to definitive agreements, due diligence, required regulatory and shareholder approvals, and other customary closing conditions. Aimei expects to provide further details after execution of a definitive business combination agreement. Hera is developing drug-delivery technologies, including biodegradable nanofiber scaffolds and AI-driven formulation capabilities.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Hera equity and equity equivalents to be acquired 100% Proposed transaction consideration would be shares of the combined public company.
non-binding letter of intent financial
"entered into a non-binding letter of intent"
A non-binding letter of intent is a preliminary document that outlines the main terms and expectations of a proposed transaction—such as a merger, acquisition, investment or partnership—without creating a legally enforceable obligation to complete the deal. Think of it as a written handshake or shopping list: it signals serious interest and sets the framework for negotiations and due diligence, which can move markets, but it does not guarantee the transaction will happen until a final, binding agreement is signed.
equity equivalents financial
"Hera’s outstanding equity and equity equivalents"
definitive business combination agreement financial
"execution of a definitive business combination agreement"
A definitive business combination agreement is the final, legally binding contract that spells out all material terms for a merger, acquisition, or similar transaction between two companies. It sets the purchase price, payment method, closing conditions, warranties, covenants, and what must happen before the deal can close — like a detailed recipe and checklist that both sides must follow. Investors care because it determines how and when ownership, risks, and value transfer, and it frames the conditions that can delay, change, or block the transaction.
biodegradable nanofiber scaffold technology medical
"proprietary biodegradable nanofiber scaffold technology"
electrospinning manufacturing platform technical
"advanced electrospinning manufacturing platform"
Proxy Statement/Prospectus regulatory
"include a preliminary proxy statement/prospectus"
A proxy statement or prospectus is a document that companies send to shareholders to provide important information about upcoming decisions or investments, such as voting on company issues or offering new shares to the public. It helps investors understand the details and risks involved, enabling them to make informed choices about their ownership or involvement with the company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is AFJK proposing to acquire from Hera?

Aimei would acquire 100% of Hera’s outstanding equity and equity equivalents in exchange for shares of the combined public company. The arrangement is described in a non-binding LOI and remains subject to definitive agreements and other closing conditions.

What approvals are needed for AFJK’s proposed Hera deal?

The proposed transaction is subject to completion of due diligence, negotiation and execution of definitive agreements, required regulatory and shareholder approvals, and other customary closing conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001979005 0001979005 2026-11-14 2026-11-14 0001979005 AFJK:OrdinarySharesParValue0.0001PerShareMember 2026-11-14 2026-11-14 0001979005 AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember 2026-11-14 2026-11-14 0001979005 AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2026-11-14 2026-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

November 14, 2026

Date of Report (Date of earliest event reported)

 

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-41880   N/A

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

10 East 53rd Street, Suite 3001

New York, NY

  10022
(Address of Principal Executive Offices)   (Zip Code)

 

86-13758131392

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share   AFJK   The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share   AFJKR   The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right   AFJKU   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01. Regulation FD Disclosure.

 

On November 14, 2026, Aimei Health Technology Co., Ltd (the “Company”) entered into a non-binding letter of intent (the “LOI”) for a business combination (the “Proposed Transaction”) with Hera Health Solutions Inc., a Tennessee biotechnology and medical device company (“Hera”).

 

Under the terms of the LOI, the Company and Hera would become a combined entity, with the Company acquiring 100% of Hera’s outstanding equity and equity equivalents in exchange for shares of the combined public company. The Company expects to announce additional details regarding the Proposed Transaction upon the execution of a definitive business combination agreement.

 

The LOI is non-binding with respect to the Proposed Transaction, except for certain provisions, including those relating to confidentiality, exclusivity, and other customary matters. The Proposed Transaction remains subject to the negotiation and execution of definitive agreements, completion of due diligence, receipt of required regulatory and shareholder approvals, and satisfaction of other customary closing conditions. There can be no assurance that any definitive agreement will be executed or that the Proposed Transaction will be consummated.

 

About Aimei Health Technology Co., Ltd

 

Aimei Health Technology Co., Ltd (Nasdaq: AFJK) is a blank check company organized as a Cayman Islands exempted company for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities.

 

About Hera Health Solutions Inc.

 

Hera Health Solutions Inc., a Delaware corporation headquartered in Memphis, Tennessee, is a pharmaceutical technology company developing next-generation drug delivery solutions through its proprietary biodegradable nanofiber scaffold technology, advanced electrospinning manufacturing platform, and AI-driven formulation capabilities. The company’s technology enables existing medicines to be reformulated into long-acting implants, patches, and other delivery formats designed to provide sustained, controlled release over extended periods. Complementing this manufacturing platform, Hera’s Hercules™ AI technology is designed to accelerate formulation development and optimize drug release performance across diverse therapeutic areas, including women’s health, infectious diseases, pain management, and metabolic disorders. Through pharmaceutical licensing and development partnerships, Hera is advancing a scalable technology platform designed to improve treatment delivery, reduce dosing frequency, and unlock new commercial opportunities for existing therapeutics.

 

Additional Information and Where to Find It

 

If a legally binding definitive agreement with respect to the Proposed Transaction is executed, the Company or a holding company to be formed in connection with the Proposed Transaction intends to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 or Form S-4, which will include a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”). A definitive Proxy Statement/Prospectus will be mailed to the Company’s shareholders as of a record date to be established for voting on the Proposed Transaction. Shareholders will also be able to obtain copies of the Proxy Statement/Prospectus, without charge, at the SEC’s website at www.sec.gov or by directing a request to: Aimei Health Technology Co., Ltd, 10 East 53rd Street, Suite 3001, New York, NY 10022.

 

This report may be deemed to be offering or solicitation material in respect of the Proposed Transaction, which will be submitted to the shareholders of the Company for their consideration. The Company urges investors, shareholders and other interested persons to carefully read, when available, the preliminary and definitive Proxy Statement/Prospectus as well as other documents filed with the SEC (including any amendments or supplements to the Proxy Statement/Prospectus, as applicable), in each case, before making any investment or voting decision with respect to the Proposed Transaction, because these documents will contain important information about the Company, Hera and the Proposed Transaction.

 

 
 

 

Participants in the Solicitation

 

The Company and its directors and executive officers may be considered participants in the solicitation of proxies with respect to the Proposed Transaction described herein under the rules of the SEC. Information about the directors and executive officers of the Company and a description of their interests in the Company and the Proposed Transaction are set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on May 4, 2026 (the “Annual Report”) and the Proxy Statement/Prospectus, when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

 

No Offer or Solicitation

 

This report shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of any business combination. This report shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

 

Forward-Looking Statements

 

Certain statements made in this report are “forward looking statements”. When used in this report, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: the inability of the Company to enter into a definitive agreement with respect to an initial business combination with Hera or any other party within the time provided in the Company’s amended and restated memorandum and articles of association, as amended; the risk that the LOI may be terminated or that the Company and Hera may be unable to agree on the terms of a definitive agreement; the Company’s ability to obtain shareholder approval to further extend the date by which it must consummate an initial business combination; the Company’s ability to maintain the listing of its securities on The Nasdaq Stock Market LLC; performance of Hera’s business; the risk that the approval of the shareholders of the Company for the Proposed Transaction is not obtained; failure to realize the anticipated benefits of the Proposed Transaction, including as a result of a delay in consummating the Proposed Transaction; the amount of redemption requests made by the Company’s shareholders and the amount of funds remaining in the Company’s trust account after satisfaction of such requests; the Company’s and Hera’s ability to satisfy the conditions to closing the Proposed Transaction; and those factors discussed in the Annual Report under the heading “Risk Factors,” and other documents of the Company filed, or to be filed, with the SEC. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 17, 2026

 

  Aimei Health Technology Co., Ltd
     
  By: /s/ Junheng Xie
  Name: Junheng Xie
  Title: Chief Executive Officer and Director
    (Principal Executive Officer)

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading